The big question
People have used honeybee products such as honey and venom as medicine for thousands of years. Researchers wanted to know whether honeybee venom can fight hard-to-treat breast cancers, such as triple-negative and HER2-enriched types, and how it might work.
What they did
The team tested honeybee venom and melittin, its main ingredient, on breast cancer cells and normal cells grown in the lab. They studied how melittin attacks the outer layer of cancer cells and built a modified version designed to target cancer cells better. They also tested melittin with the chemotherapy drug docetaxel in mice.
What they found
Venom and melittin killed triple-negative and HER2-enriched breast cancer cells most strongly. Normal skin cells needed about four times as much venom to be harmed (22.17 compared with about 5.6 to 5.8 units for two cancer cell types). Within 10 to 60 minutes, the outer layer of cancer cells began breaking down. Melittin also blocked growth signals from two proteins, EGFR and HER2, that help these cancers grow. In mice, melittin made docetaxel better at slowing tumor growth.
Why it matters
This study explains how a natural substance can single out aggressive breast cancer cells. That knowledge could help scientists design new treatments.
What it doesn't mean
This work was done in lab dishes and mice, not people. It does not mean bee stings or venom products can treat cancer; please do not try them.
Read the original abstract
Abstract reproduced from Duffy C et al., npj Precision Oncology (2020), under a CC BY 4.0 license. Plain-English summary by Womanhattan.
This summary was written with AI assistance and checked against the original paper. It is for learning, not medical advice. Talk with your care team before changing anything about your health or treatment.